Radiofrequency Ablation in Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-09-30

Study Completion Date

2017-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background/Main objective: Radiofrequency ablation (RFA) is a minimally invasive procedure widespread accepted in the treatment of different tumors, especially in the liver but its benefit is not yet well-known in breast cancer.

Our main objective is to evaluate the usefulness of RFA in \< 2cm malignant breast tumors to reduce the proportion of positive margins.

Methodology: The investigator propose a single-center, single-blind, phase I and II randomized controlled trial. Phase I:Security of the cool-tip cluster electrode assessing the potential adverse effects in three stages: initial,intermediate and final. Phase II: Randomized clinical trial, 2 parallel groups with 37 patients in each one.

Experimental group: percutaneous RFA previous to conventional lumpectomy. Control group: conventional surgery with lumpectomy. The number of positive margins in both groups, and the need of extending margin resection will be assessed intraoperatively. Inclusion criteria: women \>40 years, infiltrating ductal breast carcinoma by biopsy. The tumor must be unique, visible by ultrasound, smaller than 2cm and located \> 1 cm from the chest wall and the skin. Patients will be followed up for a period of two years to assess cosmetic result, short -term and long -term complications and recurrences.

Expected results: The "cool-tip" (cluster) ablation method reduces by at least 30% the risk of intraoperative extensions for positive margins during lumpectomy compared to conventional surgery in breast tumors with a diameter \< 2 cm.

Therefore this procedure may reduce the risk of second surgeries and the removed volume of tissue.Consequently the final cosmetic result should be improved.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Radiofrequency of Breast Cancers in Non Surgical Patients

NCT00210223

Breast Cancer

COMPLETED NA

Percutaneous Removal and Margin Ablation for Breast Cancer

NCT00574301

Breast Cancer

COMPLETED PHASE1/PHASE2

Excision Followed by Radiofrequency Ablation for Breast Cancer

NCT01153035

Breast Cancer

ACTIVE_NOT_RECRUITING NA

Feasibility Study of Cavitary Radiofrequency Ablation in Excised Mastectomy Breast Tissue

NCT02614885

Prophylactic Mastectomy

COMPLETED

Radiofrequency Ablation in Treating Patients With Early Invasive Breast Cancer or Ductal Carcinoma in Situ

NCT00388115

Breast Cancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Main objectives of the project:

* To evaluate the usefulness of radiofrequency ablation (RFA) to achieve a lower percentage of positive margins.
* To validate clinically the efficacy and safety of the method in breast tumors smaller than \< 2 cm.

Specific objectives of the project:

1. To demonstrate that , after RFA, clear margins are increased in the intraoperative pathological analysis compared to conventional surgery.

1. To quantify the number of positive margins requiring intraoperative extension in each patient, comparing the ratio in both groups.
2. To quantify the percentage of patients requiring intraoperative extension compared in both groups.
2. To demonstrate a reduction in the volume of breast tissue removed after RFA compared to conventional surgery.

1. Comparing in both groups the anteroposterior, transverse and craniocaudal diameters of the excised specimen, measured in cm, and to calculate the volume.
2. Tumor weight in grams (including extensions) will be measured to compare the weights in both groups.
3. To evaluate the differences in cosmetic outcome after RFA versus conventional surgery.

a. An international scale will be used and the scores will be compared. There will be two independent assessments, one for the physician and another for the patient.
4. To demonstrate the effectiveness of the RFA by cluster "cool-tip" electrode in the experimental group.

1. RFA is considered as complete when no viable tumor tissue is evidenced by oxidation-reduction reaction mediated by NADH-diaphorase after surgical resection. Mitochondrial dysfunction will be also evaluated by semiquantitative and quantitative method using the enzyme cytochrome c oxidase or Complex IV (COX) and tunel. Any residual viable tumor tissue will be considered as incomplete RFA.
2. Risk factors for incomplete ablations will be analyzed, especially tumor vascularization.
5. To demonstrate the safety of RFA by cluster "cool-tip" electrode in breast cancer tumors a. To quantify all side effects that may occur after the RFA and / or surgery and to correlate the complication rate in each group with severity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RFA group

A percutaneous (utlrasound-guided) radiofrequency ablation (RFA) of the tumor will be performed by the radiologist under general anesthesia. Immediately after, excision of the tumor with appropriate margin will be accomplished.

Group Type EXPERIMENTAL

Radiofrequency ablation

Intervention Type PROCEDURE

After tumor ablation and excision of the tumor, the pathologist performed a macroscopic study of the specimen,measuring the distance between the tumor and the margin in order to indicate if extensions are mandatory. Secondly and delayed, margins will be evaluated microscopically by H\&E stain. Furthermore, the tumoral viability in the ablation zone will be evaluated by NADH-diaphorase, COX and tunnel.

Control group

Normal excision of the tumor according to the protocol

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Radiofrequency ablation

After tumor ablation and excision of the tumor, the pathologist performed a macroscopic study of the specimen,measuring the distance between the tumor and the margin in order to indicate if extensions are mandatory. Secondly and delayed, margins will be evaluated microscopically by H\&E stain. Furthermore, the tumoral viability in the ablation zone will be evaluated by NADH-diaphorase, COX and tunnel.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Breast single tumor,
* Clearly visible by ultrasound,
* Diameter \< 2 cm
* Located \>1 cm from the chest wall and skin;
* Ductal carcinoma according to previous biopsy,
* \< 20% of intraductal carcinoma

Exclusion Criteria

* Breast cancer in men;
* Personal history of ipsilateral breast cancer;
* Age \<40 years;
* Pregnancy or breastfeeding;
* Suspicion of intraductal extension or multifocality by mammography or MRI;
* Tumour not visible by ultrasound;
* Diameter \> 2 cm;
* Distance to muscle or skin \<1 cm;
* Lobular carcinoma;
* Intraductal carcinoma in \> 20% of the biopsy sample
* Patients undergoing neoadjuvant chemotherapy or hormonotherapy.

Minimum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No